102148 Federal Register / Vol. 89, No. 242 / Tuesday, December 17, 2024 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to the Clinical Laboratory 

Improvement Advisory Committee 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), within the 

Department of Health and Human 

Services (HHS), is seeking nominations 

for membership on the Clinical 

Laboratory Improvement Advisory 

Committee (CLIAC). CLIAC, consisting 

of up to 20 members including the 

Chair, represents a diverse membership 

across laboratory specialties, 

professional roles (laboratory 

management, technical specialists, 

physicians, nurses), and practice 

settings (academic, clinical, public 

health), and includes a consumer 

representative. 

DATES: Nominations for membership on 

CLIAC must be received no later than 

July 1, 2025. Packages received after this 

time will not be considered for the 

current membership cycle. 

ADDRESSES: All nominations should be 

emailed to CLIAC@cdc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Heather Stang, M.S., Senior Advisor for 

Clinical Laboratories, Division of 

Laboratory Systems, Office of 

Laboratory Systems and Response, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop H24–2, Atlanta, Georgia 

30329–4027. Telephone: (404) 498– 

2769; Email: HStang@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Nominations are sought for individuals 

who have the expertise and 

qualifications necessary to contribute to 

the accomplishment of the objectives of 

the Clinical Laboratory Improvement 

Advisory Committee (CLIAC). Nominees 

will be selected based on expertise in 

the fields of microbiology (including 

bacteriology, mycobacteriology, 

mycology, parasitology, and virology), 

immunology (including 

histocompatibility), chemistry, 

hematology, pathology (including 

histopathology and cytology), or genetic 

testing (including cytogenetics); from 

representatives in the fields of medical 

technology, bioinformatics, public 

health, and clinical practice; and from 

consumer representatives. Selection of 

members is based on candidates’ 

qualifications to contribute to the 

accomplishment of CLIAC objectives 

(https://www.cdc.gov/cliac/php/about/ 

index.html). Members may be invited to 

serve up to four-year terms. 

Department of Health and Human 

Services (HHS) policy stipulates that 

committee membership be balanced in 

terms of points of view represented and 

the committee’s function. Appointments 

shall be made without discrimination 

on the basis of age, race, ethnicity, 

gender, sexual orientation, gender 

identity, HIV status, disability, and 

cultural, religious, or socioeconomic 

status. Nominees must be U.S. citizens 

and cannot be full-time employees of 

the U.S. Government. Current 

participation on Federal workgroups or 

prior experience serving on a Federal 

advisory committee does not disqualify 

a candidate; however, HHS policy is to 

avoid excessive individual service on 

advisory committees and multiple 

committee memberships. Committee 

members are Special Government 

Employees, requiring the filing of 

financial disclosure reports at the 

beginning of and annually during their 

terms. The Centers for Disease Control 

and Prevention (CDC) reviews potential 

candidates for CLIAC membership each 

year and provides a slate of nominees 

for consideration to the Secretary of 

HHS for final selection. HHS notifies 

selected candidates of their 

appointment near the start of the term 

in July or as soon as the HHS selection 

process is completed. Note that the need 

for different expertise varies from year 

to year and a candidate who is not 

selected in one year may be 

reconsidered in a subsequent year. 

Candidates should submit the 

following items: 

• Current curriculum vitae, including 

complete contact information 

(telephone numbers, mailing address, 

email address). 

• At least one letter of 

recommendation from person(s) not 

employed by HHS. Candidates may 

submit letter(s) from current HHS 

employees if they wish, but at least one 

letter must be submitted by a person not 

employed by an HHS agency (e.g., CDC, 

National Institutes of Health, Food and 

Drug Administration). 

Nominations may be submitted by the 

candidate or by the person/organization 

recommending the candidate. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–29646 Filed 12–16–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

In accordance with 5 U.S.C. 1009(d), 

the Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. 

Name of Committee: Safety and 

Occupational Health Study Section 

(SOHSS), National Institute for 

Occupational Safety and Health 

(NIOSH). 

Dates: February 4–5, 2025. 

Times: 11 a.m.–5 p.m., EST. 

Place: Teleconference. 

Agenda: The meeting will convene to 

address matters related to the conduct of 

Study Section business and for the 

Study Section to consider safety and 

occupational health-related grant 

applications. 

For Further Information Contact: 

Michael Goldcamp, Ph.D., Scientific 

Review Officer, Office of Extramural 

Programs, National Institute for 

Occupational Safety and Health, Centers 

for Disease Control and Prevention, 

1095 Willowdale Road, Morgantown, 

West Virginia 26505. Telephone: (304) 

285–5951; Email: MGoldcamp@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 242 / Tuesday, December 17, 2024 / Notices 102149 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–29645 Filed 12–16–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifiers: CMS–10765] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information (including each proposed 

extension or reinstatement of an existing 

collection of information) and to allow 

60 days for public comment on the 

proposed action. Interested persons are 

invited to send comments regarding our 

burden estimates or any other aspect of 

this collection of information, including 

the necessity and utility of the proposed 

information collection for the proper 

performance of the agency’s functions, 

the accuracy of the estimated burden, 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected, and the use of automated 

collection techniques or other forms of 

information technology to minimize the 

information collection burden. 

DATES: Comments must be received by 

February 18, 2025. 

ADDRESSES: When commenting, please 

reference the document identifier or 

OMB control number. To be assured 

consideration, comments and 

recommendations must be submitted in 

any one of the following ways: 

1. Electronically. You may send your 

comments electronically to http://

www.regulations.gov. Follow the 

instructions for ‘‘Comment or 

Submission’’ or ‘‘More Search Options’’ 

to find the information collection 

document(s) that are accepting 

comments. 

2. By regular mail. You may mail 

written comments to the following 

address: CMS, Office of Strategic 

Operations and Regulatory Affairs, 

Division of Regulations Development, 

Attention: Document Identifier/OMB 

Control Number: Room C4–26–05, 7500 

Security Boulevard, Baltimore, 

Maryland 21244–1850. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, please access the CMS PRA 

website by copying and pasting the 

following web address into your web 

browser: https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/ 

PaperworkReductionActof1995/PRAListing. 

FOR FURTHER INFORMATION CONTACT: 

William N. Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: 

Contents 

This notice sets out a summary of the 

use and burden associated with the 

following information collections. More 

detailed information can be found in 

each collection’s supporting statement 

and associated materials (see 

ADDRESSES). 

CMS–10765 Review Choice 

Demonstration for Inpatient 

Rehabilitation Facility (IRF) Services 

Under the PRA (44 U.S.C. 3501– 

3520), federal agencies must obtain 

approval from the Office of Management 

and Budget (OMB) for each collection of 

information they conduct or sponsor. 

The term ‘‘collection of information’’ is 

defined in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA 

requires federal agencies to publish a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, before 

submitting the collection to OMB for 

approval. To comply with this 

requirement, CMS is publishing this 

notice. 

Information Collections 

1. Type of Information Collection 

Request: Extension of a currently 

approved collection; Title of 

Information Collection: Review Choice 

Demonstration for Inpatient 

Rehabilitation Facility (IRF) Services; 

Use: Section 402(a)(1)(J) of the Social 

Security Amendments of 1967 (42 

U.S.C. 1395b–1(a)(1)(J)) authorizes the 

Secretary to ‘‘develop or demonstrate 

improved methods for the investigation 

and prosecution of fraud in the 

provision of care or services under the 

health programs established by the 

Social Security Act (the Act).’’ Pursuant 

to this authority, the CMS will continue 

the implementation of a Medicare 

demonstration project, which CMS 

believes will help assist in developing 

improved procedures for the 

identification, investigation, and 

prosecution of Medicare fraud occurring 

among IRFs providing services to 

Medicare beneficiaries. 

This demonstration will assist in 

developing improved procedures for the 

identification, investigation, and 

prosecution of potential Medicare fraud. 

The demonstration will ensure that 

payments for IRF services are 

appropriate through either pre-claim or 

postpayment review, thereby working 

towards the prevention and 

identification of potential fraud, waste, 

and abuse, as well as protecting the 

Medicare Trust Funds from improper 

payments while reducing Medicare 

appeals. CMS plans to continue the 

demonstration in Alabama and 

Pennsylvania, then expand to Texas, 

and California. After the initial four 

states, CMS will expand the 

demonstration to include the IRFs in 

any state that bill to Medicare 

Administrative Contractor (MAC) 

jurisdictions JJ, JL, JH, and JE. Form 

Number: CMS–10765 (OMB Control 

Number: 0938–1420); Frequency: 

Occasionally; Affected Public: Private 

Sector (Business or other for-profits and 

Not-for-profits); Number of 

Respondents: 526; Number of 

Responses: 179,910; Total Annual 

Hours: 89,955. (For questions regarding 

this collection contact Jaclyn Gray (410) 

786–3744.) 

William N. Parham, III 

Director, Division of Information Collections 

and Regulatory Impacts, Office of Strategic 

Operations and Regulatory Affairs. 

[FR Doc. 2024–29638 Filed 12–16–24; 8:45 am] 

BILLING CODE 4120–01–P 


ddrumheller on DSK120RN23PROD with NOTICES1